NCT07298421

A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2026-08-31Est. Completion: 2030-05-31

Enrollment target: 100 participants

Locations

Contact

Reference Study ID Number: CP45906 https://forpatients.roche.com/ No attachments to email below.global-roche-genentech-trials@gene.com 888-662-6728 (U.S. and Canada)

Crohn DiseaseColitis, Ulcerative

The primary objective of the study is to evaluate the efficacy of 2 different maintenance dose regimens of TEV-48574 sub…

San Diego, United StatesEst. completion Jan 5, 2026

Moderately to Severely Active Crohns Disease

This Phase III, multicenter, double-blind, placebo-controlled treat-through study will evaluate the efficacy and safety …

Dothan, United StatesEst. completion Dec 31, 2028

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.